Newsbenzinga
FDA Expands Pfizer's Ibrance Label For Frontline Maintenance In Advanced Breast Cancer
· Published
Article summary
The FDA approves Pfizer's Ibrance regimen for HR+, HER2+ metastatic breast cancer maintenance after positive Phase 3 data.
An excerpt from the original article.
Comments —
Loading comments…